4
ANZUP ANNUAL REPORT 2019
AT A GLANCE
CHAIRMAN’S REPORT AT A GLANCE
ANZUP is currently operating under its Strategic Plan 20182020. This plan builds upon our previous progress over the first ten years of our existence and provides a map for the next few years as to where we should be placing our efforts. An operational plan with clearly defined objectives, milestones, and measurable deliverables, underpins the Strategic Plan and allows the Board to see clearly where progress has been made and where work is yet to be done. The Board also recognises that the therapeutic landscape for genitourinary cancers continues to evolve rapidly and that we need to be constantly aware of new evidence and developing opportunities as they arise. ANZUP continues to be flexible and agile enough to adjust its priorities accordingly and we believe it is essential to retain this capacity. Our specific strategic priorities for the 2018-2020 Strategic Plan are:
It is an honour to provide this report on behalf of the ANZUP Board describing ANZUP’s activities over the last year. ANZUP exists to improve outcomes for people affected by genitourinary cancers. We do this by performing clinical trials to generate evidence that will inform practice and move the entire field forwards. We bring together clinicians, researchers and the broader community; anyone involved in the care of or research into genitourinary cancers is welcome as an ANZUP member. Clinical trials remain our core business, however we recognise that we have other functions and responsibilities also. ANZUP is a key provider of educational initiatives for our members and training opportunities for people developing careers in clinical and translational genitourinary cancer research. We are a community that brings people together to allow us to learn from each other and to work productively in ways that would not otherwise be possible in our otherwise isolated patches. We are a bridge to other stakeholders and to other organisations nationally and internationally with similar objectives. And we have strong links with the broader community, ensuring that we are always focussed on the issues that are important to the people for whom we care. Our communications function effectively in both directions, allowing our research findings to be disseminated broadly and to influence health care policy and practice.
Goal 1. Continue to build on and develop high quality cutting edge clinical trials. We need to continue to identify gaps and clinical needs across disease types, in order to inform concept development and investment of resources. Our trials need to have clinical impact and be able to inform and improve clinical practice. Keys to success will involve expanding the output of our subcommittees and workshops; simplifying the process of moving a concept from idea to implementation; growing collaborations with national and international partners and stakeholders, and continuing to maintain our multidisciplinary / multimodality / interprofessional philosophy of working together. Over the last year we have initiated trials in each of the disease types, and have clear pipelines for new ideas that will translate into future trials.
ANZUP global trial ENZAMET selected plenary at ASCO
Goal 2. Increase awareness, participation and access to ANZUP trials.
This goal requires increasing engagement both of our membership and the broader community. We wish to promote ANZUP activities in rural and remote areas, and continue to grow our presence and trials capacity in New Zealand and across the Asia-Pacific region and beyond. Our profile can only grow in the wider community if we continue to have effective engagement of consumers, carers, and others to allow education about and promotion of ANZUP activities and the
